Becton, Dickinson and Company (BDXA) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Becton, Dickinson and Company (BDXA) Healthcare & Pipeline Overview

Becton, Dickinson and Company (BDXA) is a leading global medical technology company, distinguished by its comprehensive portfolio of medical supplies, devices, and diagnostic products. With a market capitalization of $55.9B, BDXA serves diverse healthcare segments, emphasizing innovation and quality in a competitive medical instruments and supplies sector.

What Is the Investment Thesis for BDXA?

Becton, Dickinson and Company (BDXA) presents a compelling investment case based on its established market position, diverse product portfolio, and consistent profitability. With a market capitalization of $55.9B and a P/E ratio of 36.5, BDXA demonstrates financial stability. The company's 8.0% profit margin and 45.8% gross margin highlight operational efficiency. Growth catalysts include expanding its presence in emerging markets and introducing innovative medical technologies. Potential risks include increasing competition and regulatory changes. The dividend yield of 2.17% offers an additional incentive for investors. BDXA's commitment to innovation and strategic acquisitions positions it for sustained growth in the healthcare sector.

Based on FMP financials and quantitative analysis

BDXA Key Highlights

• Market capitalization of $55.9B reflects BDXA's significant presence in the medical technology industry.
• P/E ratio of 36.5 indicates investor confidence in BDXA's earnings potential.
• Profit margin of 8.0% demonstrates effective cost management and profitability.
• Gross margin of 45.8% highlights BDXA's ability to maintain competitive pricing and efficient production.
• Dividend yield of 2.17% provides a steady income stream for investors.

Who Are BDXA's Competitors?

BDXA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BDXA's Key Strengths?

• Strong brand reputation and established market presence.
• Diverse product portfolio with a wide range of medical devices and supplies.
• Extensive distribution network and global reach.
• Significant investment in research and development, leading to innovative products.

What Are BDXA's Weaknesses?

• Exposure to regulatory changes and compliance requirements.
• Dependence on key suppliers and potential supply chain disruptions.
• Intense competition from other medical technology companies.
• Potential for product recalls and liability claims.

What Could Drive BDXA Stock Higher?

• Launch of new diagnostic platforms in Q3 2026, expected to drive revenue growth in the diagnostic systems segment.
• Expansion of digital health solutions, creating new revenue streams and strengthening relationships with healthcare providers.
• Strategic acquisitions to expand product portfolio and geographic reach, enhancing BDXA's competitive position.
• Partnerships and collaborations to accelerate innovation and market access, leveraging external expertise and resources.

What Are the Key Risks for BDXA?

• Rich valuation — a P/E of 36.5 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
• Increasing competition from established and emerging players, potentially impacting market share and profitability.
• Pricing pressures from healthcare providers and payers, requiring BDXA to optimize its cost structure.
• Economic downturns and reduced healthcare spending, potentially affecting demand for medical devices and supplies.
• Technological obsolescence and the need for continuous innovation, requiring continuous investment in research and development.
• Regulatory changes and compliance requirements, potentially increasing costs and delaying product approvals.

What Are the Growth Opportunities for BDXA?

• Expansion in Emerging Markets: BDXA has a significant opportunity to expand its presence in emerging markets, particularly in Asia and Latin America. These regions are experiencing rapid growth in healthcare spending, driven by increasing populations and improving access to healthcare services. By tailoring its product offerings to meet the specific needs of these markets, BDXA can capture a larger share of the global medical technology market. The emerging markets healthcare sector is projected to grow at a CAGR of 8-10% over the next five years.
• New Product Development: BDXA can drive growth through continuous innovation and the development of new medical technologies. Investing in research and development to create advanced diagnostic tools, drug delivery systems, and other medical devices will enable BDXA to address unmet medical needs and gain a competitive advantage. The company's focus on innovation aligns with the industry trend towards personalized medicine and minimally invasive procedures. The global market for new medical technologies is estimated at $150 billion annually.
• Strategic Acquisitions: BDXA can pursue strategic acquisitions to expand its product portfolio and geographic reach. Acquiring companies with complementary technologies or market access can accelerate BDXA's growth and enhance its competitive position. The company has a history of successful acquisitions, and this strategy remains a key driver of its growth. The medical technology industry is highly fragmented, providing ample opportunities for consolidation.
• Digital Health Solutions: BDXA can leverage digital health technologies to enhance its product offerings and improve patient outcomes. Developing digital platforms for remote patient monitoring, data analytics, and telehealth can create new revenue streams and strengthen BDXA's relationships with healthcare providers. The digital health market is experiencing rapid growth, driven by the increasing adoption of telemedicine and the need for more efficient healthcare delivery. The global digital health market is projected to reach $379 billion by 2024.
• Partnerships and Collaborations: BDXA can collaborate with other companies and research institutions to accelerate innovation and expand its market reach. Partnering with pharmaceutical companies, biotechnology firms, and academic centers can provide access to new technologies, expertise, and markets. Collaborative efforts can also help BDXA address complex healthcare challenges and develop comprehensive solutions. Strategic partnerships are increasingly important in the medical technology industry, as companies seek to leverage each other's strengths and resources.

What Opportunities Does BDXA Have?

• Expansion in emerging markets with growing healthcare spending.
• Development of new medical technologies and digital health solutions.
• Strategic acquisitions to expand product portfolio and geographic reach.
• Partnerships and collaborations to accelerate innovation and market access.

What Threats Does BDXA Face?

• Increasing competition from established and emerging players.
• Pricing pressures from healthcare providers and payers.
• Economic downturns and reduced healthcare spending.
• Technological obsolescence and the need for continuous innovation.

What Are BDXA's Competitive Advantages?

• Strong brand reputation and established market presence.
• Diverse product portfolio with a wide range of medical devices and supplies.
• Extensive distribution network and global reach.
• Significant investment in research and development, leading to innovative products.
• Stringent regulatory approvals and high barriers to entry in the medical technology industry.

What Does BDXA Do?

Founded in 1897, Becton, Dickinson and Company (BDXA) has evolved into a global medical technology leader. Initially focused on manufacturing medical devices, BDXA expanded its portfolio to include a wide array of products and services spanning medical supplies, laboratory equipment, and diagnostic solutions. The company's evolution reflects a commitment to advancing healthcare through innovation and strategic acquisitions. BDXA's products are used in healthcare settings, research laboratories, and by individuals worldwide. Key product categories include medication delivery solutions, diagnostic systems, and biosciences products. BDXA operates globally, with a significant presence in North America, Europe, and Asia. The company competes with other major players in the medical technology industry, focusing on delivering high-quality, reliable products and solutions to improve patient outcomes and healthcare efficiency. BDXA's commitment to research and development drives its ability to introduce innovative products and maintain a competitive edge in the rapidly evolving healthcare landscape.

What Products and Services Does BDXA Offer?

• Develops and manufactures medical devices and supplies.
• Provides diagnostic systems for clinical laboratories.
• Offers biosciences products for research and drug discovery.
• Delivers medication delivery solutions for hospitals and clinics.
• Provides products for specimen management.
• Offers surgical instruments and solutions.
• Develops products for diabetes care.

How Does BDXA Make Money?

• Develops and manufactures a wide range of medical devices and supplies.
• Sells products directly to healthcare providers, research institutions, and consumers.
• Generates revenue through product sales and related services.
• Invests in research and development to create innovative products.

What Industry Does BDXA Operate In?

Becton, Dickinson and Company operates within the medical instruments and supplies industry, a sector characterized by continuous innovation and increasing demand for advanced healthcare solutions. The global medical devices market is projected to reach $600 billion by 2028, driven by an aging population, rising prevalence of chronic diseases, and technological advancements. BDXA competes with companies like AKYA, AVGR, COR, GMVD, and IVC, focusing on delivering high-quality, reliable products and solutions. The industry is subject to stringent regulatory requirements and intense competition, requiring companies to invest heavily in research and development to maintain a competitive edge.

Who Are BDXA's Key Customers?

• Hospitals and clinics
• Clinical laboratories
• Research institutions
• Pharmaceutical companies
• Individual patients

F-Score 7/9Financial Health

Becton, Dickinson and Company's Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 2.12 places it in the grey zone, a middle ground that warrants monitoring.

Quarterly Financial Performance: Becton, Dickinson and Company

Revenue for Becton, Dickinson and Company came in at $4.71B during Q1 2026, a 10.2% contraction versus the preceding quarter. The company recorded a net loss of $311.0M, with diluted EPS of $-1.11. Revenue has contracted over three consecutive quarters, which investors in this large-cap Healthcare stock should monitor closely. Across the four most recent quarters, BDXA averaged $0.99 in diluted EPS.

BDXA Valuation & Market Position

With a $55.9B market cap, Becton, Dickinson and Company sits in the large-cap segment of the market. Relative to its peer group, BDXA's quantitative score of 73/100 is roughly in line with the peer average of 65/100.

ROE 5%Key Financial Metrics

Return on equity for Becton, Dickinson and Company stands at 4.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.2%, showing how much profit it generates from its asset base. BDXA trades at a trailing price-to-earnings ratio of 36.46, above the Healthcare sector average of ~23x. Its free cash flow yield is 5.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.94 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 2.7%, the inverse of the P/E and a quick read on earnings relative to price.

Company Profile

Becton, Dickinson and Company operates in the Medical - Instruments & Supplies industry within the Healthcare sector. BDXA has traded publicly since 2017.

BDXA Financials

BDXA Latest News

No recent news available for BDXA.

BDXA Analyst Consensus

BDXA MoonshotScore

What Investors Ask About Becton, Dickinson and Company (BDXA) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources